Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
only presenting VAL RNS ..... Bladey ..
which tend to go like this .......... Fantastic result .. however we need to increase dosage 2017
year later
Fantastic result but we need to increase dosage .. 2018
2020 Sept 28 ... fantastic result but we need another trial to test dosage ....
then in March after that RNS ............. they upped the dose again !! why ?
Based on these results, the MHRA approved an extension to the trial (announced 18/12/17), allowing for an intra-patient dose escalation of up to 16mg/kg. This segment of the trial is in the concluding stages of its Phase l/ll (announced 17/10/18) and is progressing with patients to establish the maximum tolerated acute dose in Humans (MTD). This part of the study is also further establishing potential efficacy levels and pharmacokinetic / pharmacodynamic profiles as well, providing supporting information with respect to the optimal therapeutic regimes to be tested in the subsequent late stage clinical trials.
why don't you read the 2018 Val 201 update .....................
Update on VAL201 Clinical Trial
Mon, 10th Dec 2018 07:00
"This is fantastic news and it heralds our entry into the pivotal stage of VAL201's clinical trial programme. I thank the team for their hard work in delivering these very encouraging and positive outcomes".
water is safe ........... but has no efficacy in this indication
its not if it has efficacy it has some ............... that is the reason why they kept upping the dose .......
the issue is ... can you get to the efficacy of what currently is prescribed ?
just sent you links of similar trials but using 100's of patients .. not 12
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30688-6/fulltext
its more complicated ......
Interpretation
Enzalutamide showed activity as a second-line novel androgen receptor pathway inhibitor, whereas abiraterone acetate did not, leading to a longer time to second PSA progression for the sequence of abiraterone followed by enzalutamide than with the opposite treatment sequence. Our data suggest that using a sequencing strategy of abiraterone acetate followed by enzalutamide provides the greatest clinical benefit.
this is what its supposed to look like
https://pubmed.ncbi.nlm.nih.gov/25698064/
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
suzy also posted ....
Dr Suzy Dilly, CEO of ValiSeek, commented: "The external validation from both the Advisory Board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market. These developments are a valuable addition to our licensing package, clarifying the final stages of clinical testing towards commercial use."
you are wrong .......... nothing has changed
the results indicate you need another trial to prove them ................. and to sort out the dosage and strategy ... that is called "back to square one"
ATB
well done ... You are correct, VAL201 has to be able to compete against current standard of care , the reason why they keep upping the dose is because it didn't . You have no idea how long the efficacy lasts ... because of resistance, and the patients numbers are so small that its difficult to generate statistical significance have you not seen this before in other trials By the CEO ? history repeats
C7 .. if you paid 55p back in 2012/13 ... in scancell you have still a very good chance over the next 6 months to actually move into profit ...
lets see who gets to 55p in 6 months time ..
and who holds it
Firelighters run off before ... 999
C7 .... they have not announced trial results .. erh .......... not that i saw anyway, when Scancell announce results you get the full package including comparison ... swimmer charts .. etc
But then they are not research scientists .. they have not "invented" 201 or anything to my knowledge .. with no in house labs etc .. desk phone and computer ..... = Bio Tech
Thus, although this is a murine T-cell epitope, this predicts the benefit of using SARS-CoV-2 vaccines that also include the N protein, as this protein is likely to induce immune cells that also recognize CoVs in future outbreaks. Hence, including N and/or other structural proteins in addition to spike-related sequences adds the benefits of increasing immunogenicity and ensures a more future-proof vaccine design.
More Proof that Scancells approach should yield excellent results .. with the benefit also of the potency of the immunobody vaccine.
again with the Daily mail, and the times article ............ its a further buy indicator